Voltar
Revisão Revisado por pares
BIBTEX RIS

Molecular conformation and biological activity of central nervous system active drugs

1982; Wiley; Volume: 2; Issue: 4 Linguagem: Inglês

10.1002/med.2610020404

ISSN

1098-1128

Autores

Peter R. Andrews, Edward J. Lloyd,

Tópico(s)

Pharmacological Receptor Mechanisms and Effects

Resumo

Medicinal Research ReviewsVolume 2, Issue 4 p. 355-393 Article Molecular conformation and biological activity of central nervous system active drugs P. R. Andrews, P. R. Andrews School of Pharmaceutical Chemistry, Victorian College of Pharmacy Ltd., 381 Royal Parade, Parkville, Victoria 3052, AustraliaSearch for more papers by this authorE. J. Lloyd, E. J. Lloyd School of Pharmaceutical Chemistry, Victorian College of Pharmacy Ltd., 381 Royal Parade, Parkville, Victoria 3052, AustraliaSearch for more papers by this author P. R. Andrews, P. R. Andrews School of Pharmaceutical Chemistry, Victorian College of Pharmacy Ltd., 381 Royal Parade, Parkville, Victoria 3052, AustraliaSearch for more papers by this authorE. J. Lloyd, E. J. Lloyd School of Pharmaceutical Chemistry, Victorian College of Pharmacy Ltd., 381 Royal Parade, Parkville, Victoria 3052, AustraliaSearch for more papers by this author First published: October/December 1982 https://doi.org/10.1002/med.2610020404Citations: 43AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 J. R. Cooper, F. E. Bloom and R. H. Roth, The Biochemical Basis of Neuropharmacology, 2nd ed., Oxford University Press, New York, 1974. 2 Z. L. Kruk and C. J. Pycock, Neurotransmitters and Drugs, Croom Helm, London, 1979. 3 A. Albert, Selective Toxicity, 6th ed., Chapman and Hall, London, 1979. 4 P. Gund, in Annual Reports in Medicinal Chemistry, H.-J. Hess, Ed., Academic, New York, 1979, Vol. 14, pp. 299–308. 5 J. P. Tollenaere, H. Moereels and L. A. Raymaekers, Atlas of the Three-Dimensional Structure of Drugs, Elsevier, Amsterdam, 1979. 6 W. L. Duax, in Molecular Structure by Diffraction Methods, L. E. Sutton and M. R. Truter, Eds., The Chemical Society, London, 1978, Vol. 6, pp. 261–328. 7 W. G. Richards, Quantum Pharmacology, Butterworths, London, 1977. 8 L. M. Jackman and S. Sternhell, Applications of Nuclear Magnetic Resonance Spectroscopy in Organic Chemistry, 2nd ed., Pergamon, New York, 1969. 9 D. W. Larsen, T. A. Smentkowski, B. A. Soltz, and F. E. Stary, J. Am. Chem. Soc., 100, 4982 (1978). 10 J. J. Kaufman, H. E. Popkie, and P. C. Hariharan, Computer-Assisted Drug Design, ACS Symposium Series No. 112, American Chemical Society, Washington, DC, 1979, p. 415. 11 E. C. Olson and R. E. Christoffersen, Eds., Computer-Assisted Drug Design, ACS Symposium Series No. 112, American Chemical Society, Washington, DC, 1979. 12 L. L. Iversen, S. D. Iversen and S. H. Snyder, Eds., Handbook of Psychopharmacology, Plenum, New York, 1978, Vol. 10. 13 P. Seeman, Pharm. Rev., 32, 229 (1981). 14 C. J. E. Niemegeers and P. A. J. Janssen, Life Sci., 24, 2201, (1979). 15 R. Bergin and D. Carlström, Acta Cryst., B24, 1506 (1968). 16 T. M. Bustard and R. S. Egan, Tetrahedron, 27, 4457 (1971). 17 C. J. Grol and H. Rollema, J. Pharm. Pharmac., 29, 153 (1977). 18 W. Klyne and V. Prelog, Experientia, 16, 521 (1960). 19 H. L. Komiskey, J. F. Bossart, D. D. Miller, and P. N. Patil, Proc. Natl. Acad. Sci. USA, 75, 2641 (1978). 20 A. S. Horn and S. H. Snyder, Proc. Natl. Acad. Sci. USA, 68, 2325 (1971). 21 N. Kumar and P. C. Jain, in Progress in Drug Research, E. Jucker, Ed., Birkhäuser Verlag, Basel, 1977, Vol. 21, pp. 409–465. 22 A. S. Horn and J. R. Rodgers, J. Pharm. Pharmacol., 32, 521 (1980). 23 J. W. Kebabian and D. B. Calne, Nature, 277, 93 (1979). 24 N. Camerman, L. Y. Y. Chan, and A. Camerman, Mol. Pharmacol., 16, 729 (1979). 25 N. J. Bach, E. C. Kornfeld, N. D. Jones, M. O. Chaney, D. E. Dorman, J. W. Paschal, J. A. Clemens, and E. B. Smalstig, J. Med. Chem., 23, 481 (1980). 26 L. G. Humber, A. H. Philipp, F. T. Bruderlein, M. Götz, and K. Voith, in ref. 11, pp. 227–241. 27 L. G. Humber, N. Sideridis, A. A. Asselin, F. T. Bruderlein, and K. Voith, J. Med. Chem., 21, 1225 (1978). 28 G. L. Olson, H.-C. Cheung, K. D. Morgan, J. F. Blount, L. Todaro, L. Berger, A. B. Davidson, and E. Boff, J. Med. Chem., 24, 1026 (1981). 29 J. P. Tollenaere, H. Moereels, and L. A. Raymaekers, in Drug Design, E. J. Ariëns, Ed., Academic, New York, 1980, Vol. 10, pp. 71–118. 30 C. A. Harbert, J. J. Plattner, W. M. Welch, A. Weissman, and B. K. Koe, Mol. Pharm., 17, 38 (1980). 31 R. A. Lahti, Naturwiss enschaften, 66, 403 (1979). 32 M. L. Post, O. Kennard, and A. S. Horn, Nature, 252(5483), 493 (1974). 33 R. J. Abraham, L. J. Kricka and A. Ledwith, J. Chem. Soc. Perkin Trans. 2(14), 1648 (1974). 34 A. R. Martin, V. M. Paradkar, G. W. Peng, R. C. Speth, H. I. Yamamura, and A. S. Horn, J. Med. Chem., 23, 865 (1960). 35 T. de Paulis, D. Kelder and S. B. Ross, Mol. Pharmacol., 14, 596 (1978). 36 R. A. Maxwell and H. L. White, in Handbook of Psychopharmacology, L. L. Iversen, S. D. Iversen and S. H. Snyder, Eds., Plenum, New York, 1978, Vol. 14, pp. 83–155, and references therein. 37 G. L. Grunewald, T. J. Reitz, J. A. Ruth, S. Vollmer, L. E. Eiden, and C. O. Rutledge, Biochem. Pharmacol., 28, 417 (1979). 38 R. A. Maxwell, R. M. Ferris, J. Burcsu, E. C. Woodward, D. Tang, and K. Williard, J. Pharm. Exp. Ther., 191, 418 (1974). 39 M. Wilhelm and R. Kuhn, Pharmakopsychiatr. Neuro-Psychopharmakol. 3, 317 (1970). 40 J. B. Stenlake, Foundations of Molecular Pharmacology, Athlone, London, 1979. 41 R. W. Baker, C. Chothia, P. Pauling, and H. P. Weber, Mol. Pharmacol., 9, 23 (1973). 42 O. Kennard, C. Giacovazzo, A. S. Horn, R. Mongiorgi, and L. Riva di Sanseverino, J. Chem. Soc. Perkin Trans., B2, 1160 (1974). 43 R. Bergin and D. Carlström, Acta Cryst., B27, 2146 (1971). 44 B. Pullman, J.-L. Coubeils, P. Courrière, and J.-P. Gervois, J. Med. Chem., 15, 17 (1972). 45 B. Pullman, H. Berthod, and P. Courrière, Int. J. Quant. Chem. Quant. Biol. Symp., 1, 93 (1974). 46 G. G. Hall, C. J. Miller, and G. W. Schnuelle, J. Theoret. Biol., 53, 475 (1975). 47 G. L. Grunewald, M. W. Creese, and D. E. Walters, in ref. 11, p. 439. 48 G. A. Neville, R. Deslauriers, B. J. Blackburn, and I. C. P. Smith, J. Med. Chem., 14, 717 (1971). 49 K. Bailey, J. Pharm. Sci., 60, 1232 (1971). 50 K. Bailey, A. W. By, K. C. Graham, and D. Verner, Can. J. Chem., 49, 3143 (1971). 51 G. E. Wright, Tetrahedron Lett., 1097 (1973). 52 J. A. Ruth, G. L. Grunewald and C. O. Rutledge, J. Pharm. Exp. Therap., 204, 615 (1978). 53 G. L. Grunewald, T. J. Reitz, A. Hallett, C. O. Rutledge, S. Vollmer, J. M. Archuleta III, and J. A. Ruth, J. Med. Chem., 23, 614–620 (1980). 54 J. Tuomisto, L. Tuomisto, and T. L. Pazdernik, J. Med. Chem., 19, 725 (1976). 55 P. Brawley and J. C. Duffield, Pharm. Rev., 24, 31 (1972). 56 A. S. Horn, M. L. Post, O. Kennard, and L. Riva di Sanseverino, J. Pharm. Pharmac., 27, 13 (1975). 57 D. Tsoucaris, C. de Rango, G. Tsoucaris, C. H. Zelwer, R. Parthasarathy, and F. E. Cole, Cryst. Struct. Comm., 2, 193 (1973). 58 S. R. Ernst and R. W. Cagle, Jr., Acta Cryst., B29, 1543 (1973). 59 S. Kang, C. L. Johnson and J. P. Green, Mol. Pharmacol., 9, 640 (1973). 60 H. J. R. Weintraub, D. E. Nichols, A. Makriyannis, and S. W. Fesik, J. Med. Chem., 23, 339 (1980). 61 K. Bailey and A. A. Grey, Can. J. Chem., 50, 3876 (1972). 62 L. Pierri, I. H. Pitman, I. D. Rae, D. A. Winkler, and P. R. Andrews, J. Med. Chem., in press. 63 L. Bernardi and W. Barbieri, Tetrahedron, 21, 2539 (1965). 64 H. P. Weber, in Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects, M. Goldstein et al., Eds., Raven, New York, 1980. 65 N. Camerman, L. Y. Y. Chan, and A. Camerman, Mol. Pharmacol., 16, 729 (1979). 66 C. Chothia and P. Pauling, PNASUS, 63 1063 (1969). 67 D. E. Nichols, W. E. Pfister, and G. K. W. Yim, Life Sci., 22, 2165 (1978). 68 A. Spinks and W. S. Waring, in Progress in Medicinal Chemistry, Ellis and West, Eds., Butterworths, London, 1963, Vol. 3. 69 P. Skolnick and S. M. Paul, Med. Res. Rev., 1, 3 (1981). 70 P. R. Andrews, J. Med. Chem., 12, 761 (1969). 71 T. B. Patrick and R. R. Bresee, J. Pharm. Sci., 65, 1066 (1976). 72 P. R. Andrews and A. S. Buchanan, Biochem. Pharmacol., 20, 1599 (1971). 73 H. Downes, R. S. Perry, R. E. Ostlund, and R. Karler, J. Pharmacol. Exp. Ther., 175, 692 (1970). 74 B. W. Metcalf, Biochem. Pharmacol., 28, 1705 (1979). 75 P. R. Andrews and G. A. R. Johnston, Biochem. Pharmacol., 28, 2697 (1979). 76 P. Krogsgaard-Larsen, G. A. R. Johnston, D. Lodge, and D. R. Curtis, Nature, 268, 53 (1977). 77 P. R. Andrews and G. A. R. Johnston, J. Theor. Biol., 79, 263 (1979). 78 P. Krogsgaard-Larsen, and A. V. Christensen, Ann. Rep. Med. Chem., 15, 41 (1980). 79 P. R. Andrews and G. P. Jones, Int. J. Quantum Chem. Quantum Biol. Symp., 6, 439 (1979). 80 M. Karobath, P. Supavilai, P. Placheta, and W. Sieghart, Adv. Biosci., 31, 229 (1981). 81 H. Möhler, J. G. Richards, and J.-Y. Wu, Proc. Natl. Acad. Sci. USA, 78, 1935 (1981). 82 P. Krogsgaard-Larsen and J. Arnt, Brain Res. Bull., 5, 867 (1980). 83 M. K. Ticku, Biochem. Pharmacol., 30, 1573 (1981). 84 A. Camerman and N. Camerman, Acta Crystallogr., B27, 2205, (1971). 85 A. Camerman and N. Camerman, J. Am. Chem. Soc., 94, 268, (1972). 86 A. Camerman and N. Camerman, Science, 168, 1457, (1970). 87 N. Camerman and A. Camerman, Mol. Pharmacol., 7, 406, (1971). 88 N. Camerman and A. Camerman, J. Am. Chem. Soc., 94, 8553 (1972). 89 A. Camerman and N. Camerman, Can. J. Chem., 53, 2194 (1975). 90 A. Camerman and N. Camerman, Proc. Natl. Acad. Sci. USA, 74, 1264 (1977). 91 J. K. Fawcett, N. Camerman, and A. Camerman, Can. J. Chem., 55, 3631 (1977). 92 A. Camerman and N. Camerman, in Molecular and Quantum Pharmacology, E. Bergmann and B. Pullman, Eds., Reidel, Dordrecht, 1974. 93 A. Camerman and N. Camerman, in Antiepileptic Drugs: Mechanism of Action, G. H. Glaser, J. K. Penry, and D. M. Woodbury, Eds., Raven, New York, 1980. 94 P. G. Jones and O. Kennard, J. Pharm. Pharmac., 30, 815 (1978). 95 P. R. Andrews and J. A. Defina, unpublished. 96 G. Romeo, M. C. Aversa, P. Giannetto, M. G. Vigorita, and P. Ficarra, Org. Mag. Res., 12(10), 593 (1979). 97 H.-D. Höltje, Arch. Pharm. (Weinheim), 310, 650 (1977). 98 B. Pullman, J. L. Coubeils, and Ph. Courrière, J. Theoret. Biol., 35, 375 (1972). 99 P. R. Andrews and G. P. Jones, Eur. J. Med. Chem., 16, 139 (1981). 100 G. P. Jones and P. R. Andrews, J. Med. Chem., 23, 444 (1980). 101 L. H. Sternbach, F. D. Sancilio, and J. F. Blount, J. Med. Chem., 17, 374 (1974). 102 G. Gilli, V. Bertolasi, M. Sacerdoti, and P. A. Borea, Acta Crystallogr., B33, 2664 (1977). 103 G. Gilli, V. Bertolasi, M. Sacerdoti, and P. A. Borea, Acta Crystallogr., B34, 2826 (1978). 104 P. P. Williams, Acta Crystallogr., B29, 1572 (1973). 105 H. J. R. Weintraub, Int. J. Quantum Chem. Quantum Biol. Symp., 4, 111 (1977). 106 A. Camerman and N. Camerman, Acta Crystallogr., in press. 107 P. R. Andrews, A. J. Jones, G. P. Jones, A. Marker, and E. A. Owen, Eur. J. Med. Chem., 16, 145 (1981). 108 G. P. Jones and P. R. Andrews, J. Cryst. Mol. Struct., 11, 125 (1981). 109 P. R. Andrews and G. P. Jones, J. Cryst. Mol. Struct., 11, 135 (1981). 110 G. P. Jones and P. R. Andrews, J. Cryst. Mol. Struct., 11, 145 (1981). 111 J. P. Bideau, C. R. Acad. Sci. Paris, C272, 757 (1971). 112 B. M. Craven and C. Cusatis, Acta Cryst., B25, 2291 (1969). 113 B. M. Craven and E. A. Vizzini, Acta Cryst., B25, 1993 (1969). 114 P. H. Smit and J. A. Kanters, Acta Cryst., B30, 784 (1974). 115 P. R. Andrews, G. P. Jones, L. C. Mark, and D. A. Winkler, submitted. 116 C. Hansch, A. R. Steward, S. M. Anderson, and D. Bentley, J. Med. Chem., 11, 1 (1968). 117 F. S. LaBella, Can. J. Physiol. Pharmacol., 59, 432 (1981). 118 P. R. Andrews and L. C. Mark, Anesthesiology, in press. 119 C. C. Pfeiffer, Science, 124, 29, (1956). 120 A. J. Trevor, M. P. Marietta, and W. L. Way, Pharmacologist, 18, 214 (1976). 121 J. Knabe, W. Rummel, H. P. Büch, and N. Franz, Arzneime-Forsch., 7, 1048 (1978). 122 E. Frommel, P. Gold-Aubert, and C. Fleury, Arch. Int. Pharmacodyn., 122, 15, (1959). 123 P. R. Andrews, G. P. Jones, and D. Lodge, Eur. J. Pharmacol., 55, 115 (1979). 124 A. S. Horn and J. R. Rodgers, J. Pharm. Pharmac., 29, 257 (1977). 125 C. R. Beddell, L. A. Lowe, and S. Wilkinson, in Progress in Medicinal Chemistry, G. P. Ellis and G. B. West, Eds., Elsevier, Holland, 1980, Vol. 17. 126 A. H. Beckett and A. F. Casy, J. Pharm. Pharmac., 6, 986 (1954). 127 A. F. Casy, Prog. Drug Res., 22, 149 (1978). 128 D. S. Fries and P. S. Portoghese, J. Med. Chem., 19, 1155 (1976). 129 A. P. Feinberg, I. Creese and S. H. Snyder, Proc. Natl. Acad. Sci. USA, 73, 4215 (1976). 130 F. A. Gorin and G. R. Marshall, Proc. Natl. Acad. Sci. USA, 74, 5179 (1977). 131 G. H. Loew and D. S. Berkowitz, J. Med. Chem., 18, 656 (1975). 132 S. K. Burt and G. H. Loew, in Endogenous and Exogenous Opiate Agonists and Antagonists, E. Way, Ed., Pergamon, New York, 1980. 133 S. K. Burt, G. H. Loew and G. M. Hashimoto, Ann. N.Y. Acad. Sci., in press. 134 P. A. J. Janssen and J. P. Tollenaere, in Neurochemical Mechanisms of Opiates and Endorphins, H. H. Loh and D. H. Ross, Eds., Raven, New York, 1979. 135 P. R. Andrews and E. J. Lloyd, submitted. Citing Literature Volume2, Issue4October/December 1982Pages 355-393 ReferencesRelatedInformation

Referência(s)